Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials.

Costabel, Ulrich; Behr, Jürgen; Crestani, Bruno; Stansen, Wibke; Schlenker-Herceg, Rozsa; Stowasser, Susanne; Raghu, Ganesh

Costabel, Ulrich; Behr, Jürgen; Crestani, Bruno; Stansen, Wibke; Schlenker-Herceg, Rozsa; Stowasser, Susanne; Raghu, Ganesh.

Afiliação

Costabel U; Ruhrlandklinik, University Hospital, University of Duisburg-Essen, Essen, Germany.
Behr J; Medizinische Klinik und Poliklinik V, University of Munich (LMU) and Asklepios Klinik München-Gauting, Member of the German Center for Lung Research, Munich, Germany.
Crestani B; APHP, Hôpital Bichat, Service de Pneumologie A, DHU FIRE; INSERM, Unité 1152; Université Paris Diderot, Paris, France.
Stansen W; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Schlenker-Herceg R; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.
Stowasser S; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Raghu G; University of Washington, Seattle, WA, USA. graghu@uw.edu.

Respir Res ; 19(1): 167, 2018 Sep 03.

Article em En | MEDLINE | ID: mdl-30176872

Assuntos

Antiácidos/uso terapêutico; Fibrose Pulmonar Idiopática/diagnóstico; Fibrose Pulmonar Idiopática/tratamento farmacológico; Idoso; Feminino; Humanos; Fibrose Pulmonar Idiopática/epidemiologia; Masculino; Pessoa de Meia-Idade; Estudos Prospectivos; Resultado do Tratamento

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrose Pulmonar Idiopática / Antiácidos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google